Currently marketed fluoroquinolones enjoy an admirable safety profile that is not matched by any other antibiotic group. The widespread use of fluoroquinolones in the elderly, who are susceptible to cardiac arrhythmias because of underlying heart diseases, metabolic derangement and use of anti-arrhythmic agents and other medications that prolong the QT interval, has raised the issue of the cardiac safety of the newer fluoroquinolones. This issue had been further stressed by the unexpected removal from the market of several fluoroquinolones because of safety issues, including cardiotoxic effects. A recent leading article addressed this issue, and the aim of the present article is to update the reader on this matter. 1